Clinical Data
Phase 3 mortality analysis
Lower all-cause mortality for PREVYMIS vs placebo1

Data through week 24 post-transplant P=0.0401.1
Data through week 48 post-transplant P=0.2117, not significant.1
PREVYMIS™
(letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL
Clinical Data
Lower all-cause mortality for PREVYMIS vs placebo1
Data through week 24 post-transplant P=0.0401.1
Data through week 48 post-transplant P=0.2117, not significant.1
1. Data available on request from Merck Professional Services-DAP, WP1, PO Box 4, West Point, PA 19486-0004. Please specify information package US-CYT-00437.
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Drug interactions may occur based on results from studies. Drug interactions may also occur based on predicted interactions. Potentially significant drug interactions include, but are not limited to, the following (information below applies to co-administration of PREVYMIS and the concomitant drug without cyclosporine, unless otherwise indicated):
Before prescribing PREVYMIS, please read the accompanying Prescribing Information. The Patient Information also is available.